Table 3.
The Barcelona cohort: clinical and imaging variables at baseline
| MS baseline | MS 2-year FU | HC | |
|---|---|---|---|
| n = 251 | n = 235 | n = 24 | |
| Age | 43.5 (10.7) | 44.8 (10.8) | 39.4 (10.2) |
| Female | 180 (72%) | 169 (72) | 19 (79%) |
| Age at disease onset (years) | 31.4 (25.7–38.9) | 31.1 (25.5–38.9) | – |
| Disease duration (years) | 9.9 (2.4–15.7) | 10.3 (3.6–17) | – |
| Subtype | |||
| CIS | 22 (9) | 4 (2) | |
| RRMS | 203 (81) | 183 (887) | |
| SPMS | 20 (8) | 16 (8) | |
| PPMS | 6 (2) | 6 (3) | – |
| EDSS | 2.0 (0–6.5) | 2.0 (0–7.0) | – |
| MSSS | 2.9 (1.8–4.9) | 2.7 (1.7–4.2) | – |
| ARMS | 3.2 (2.1–4.9) | 3 (1.9–4.6) | – |
| T25WT (sec) | 4.2 (3.8–5.2) | 4.5 (3.9–5.6) | – |
| 9HPT (sec) | 20.8 (19–23.5) | 21 (18.7–24) | – |
| SDMT (# symbols) | 50.1, 13.2 | 51.6, 13.2 | – |
| SL25 (# letters) | 27 (16.2–30.5) | 22.5 (13–30) | – |
| HCVA (LogMAR) | 0 (-0.1–0) | 0 (-0.1, 0.1) | – |
| DMD | |||
| Untreated | 122 (48) | 23 (26) | – |
| Interferon beta | 67 (27) | 35 (39) | – |
| Glatiramer acetate | 28 (11) | 13 (15) | – |
| Teriflunomide | 8 (3) | 1 (1) | – |
| Fingolimod | 9 (4) | 9 (10) | – |
| Dimethyl-Fumarate | 3 (1) | 2 (2) | – |
| Natalizumab | 12 (5) | 4 (5) | – |
| Other | 2 (1)a | 2 (2)b | – |
| MRI | |||
|---|---|---|---|
| T2 lesion volume (cm3) | 5.1 (2.2–11.4) | 2.1 (0–7.8) | – |
| NBV (cm3) | 1505 (124) | 1405 (97.5) | – |
| NGMV (cm3) | 722.4 (65.3) | 662.6 (48.5) | – |
| NWMV (cm3) | 778.1 (66.7) | 742.4 (63.3) | – |
| OCT (µm) | |||
|---|---|---|---|
| pRNFL (µm) | 90.5 (80.5–100.2) | 88.2 (79.4–97.6) | – |
| mRNFL (µm) | 26.4 (23.7–28.4) | 25.9 (23.6–28.4) | – |
| GCIPL (µm) | 68.2 (61.8–74.5) | 67.1 (59.9–73.5) | – |
| INL (µm) | 37.2 (34.9–39.1) | 37.1 (35.1–39.1) | – |
| ORL (µm) | 110.1 (106.1–113.9) | 109.6 (105.5–113.1) | – |
Disability scales are shown as the mean and standard deviation or range, except for the EDSS which is displayed as the median (range)
aOther DMD baseline: alemtuzumab: 9, rituximab: 7, ocrelizumab: 1, daclizumab: 2
bOther DMD year 2: alemtuzumab: 13, rituximab: 11, ocrelizumab: 16, cladribine: 3